Table 6.
Comparison of clinical and biological findings between hematological patients (HAEs) and non-hematological patients (HAEs)
| Variable | HAE n = 113 |
Non-HAE n = 119 |
p value |
|---|---|---|---|
| Certainty of diagnosis, n (%) | 0.010 | ||
| Proven | 31 (27.4) | 52 (43.7) | |
| Probable | 82 (72.6) | 67 (56.3) | |
| Underlying conditions, n (%) | |||
| Neutropenia | 101 (89.4) | 9 (7.6) | <0.001 |
| Corticosteroids therapy | 42 (37.2) | 63 (52.9) | 0.016 |
| Prolonged antibiotic therapy | 51 (45.1) | 47 (39.5) | 0.385 |
| Immunosuppressive therapy | 24 (21.2) | 15 (12.6) | 0.079 |
| Cytomegalovirus infection | 7 (6.2) | 1 (0.8) | 0.025 |
| Diabetes | 8 (7.1) | 27 (22.7) | 0.001 |
| Mechanical ventilation | 2 (1.8) | 24 (20.2) | <0.001 |
| Surgery | 2 (1.8) | 21 (17.6) | <0.001 |
| Site of localization, n (%) | |||
| Lung | 94 (83.2) | 89 (74.8) | 0.117 |
| Eye | 0 | 10 (8.4) | 0.002 |
| Blood | 8 (7.1) | 5 (4.2) | 0.341 |
| Multiple | 16 (14.1) | 14 (11.8) | 0.587 |
| Mean time between symptoms and diagnosis, no. days | 11.06 (1–57) | 13.65 (0–65) | 0.900 |
| Fever, n (%) | 103 (91.1) | 69 (58.0) | <0.001 |
| GM antigenemia positive for invasive aspergillosis, n (%) | 82/86 (95.3) | 38/79 (48.1) | <0.001 |
| Mean time between symptoms and therapy, no. days | 12 (0–57) | 14.3 (0–65) | 0.147 |
| Antifungal prophylaxis, n (%) | 75 (66.4) | 10 (8.4) | <0.001 |
| Empirical therapy, n (%) | 44 (38.9) | 26 (21.8) | 0.005 |
| Combination therapy, n (%) | 23/109 (21.1) | 14/114 (12.3) | 0.076 |
| Computed tomography signs recorded in patients with pulmonary involvement, n (%) | |||
| Halo sign | 33/94 (35.1) | 10/89 (11.2) | <0.001 |
| Areas of consolidation | 21/94 (22.3) | 14/89 (15.7) | 0.256 |
| Nodules | 14/94 (14.9) | 10/89 (11.2) | 0.464 |
| Crude mortality, n (%) | 50 (44.2) | 42 (35.3) | 0.163 |